# Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder

> **NCT06943573** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Lakshmi N Yatham** · enrollment: 90 (estimated)

## Conditions studied

- Bipolar II Depression

## Interventions

- **DRUG:** psilocybin (25 mg)
- **DRUG:** psilocybin 1mg micro-dose

## Key facts

- **NCT ID:** NCT06943573
- **Lead sponsor:** Lakshmi N Yatham
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06943573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06943573, "Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06943573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*